Literature DB >> 31570001

Estrogen-related receptor β activation and isoform shifting by cdc2-like kinase inhibition restricts migration and intracranial tumor growth in glioblastoma.

Deanna M Tiek1, Subreen A Khatib1,2, Colin J Trepicchio1, Mary M Heckler1, Shailaja D Divekar1, Jann N Sarkaria3, Eric Glasgow1, Rebecca B Riggins1.   

Abstract

Glioblastoma (GBM; grade 4 glioma) is a highly aggressive and incurable tumor. GBM has recently been characterized as highly dependent on alternative splicing, a critical driver of tumor heterogeneity and plasticity. Estrogen-related receptor β (ERR-β) is an orphan nuclear receptor expressed in the brain, where alternative splicing of the 3' end of the pre-mRNA leads to the production of 3 validated ERR-β protein products: ERR-β short form (ERR-βsf), ERR-β2, and ERR-β exon 10 deleted. Our prior studies have shown the ERR-β2 isoform to play a role in G2/M cell cycle arrest and induction of apoptosis, in contrast to the function of the shorter ERR-βsf isoform in senescence and G1 cell cycle arrest. In this study, we sought to better define the role of the proapoptotic ERR-β2 isoform in GBM. We show that the ERR-β2 isoform is located not only in the nucleus but also in the cytoplasm. ERR-β2 suppresses GBM cell migration and interacts with the actin nucleation-promoting factor cortactin, and an ERR-β agonist is able to remodel the actin cytoskeleton and similarly suppress GBM cell migration. We further show that inhibition of the splicing regulatory cdc2-like kinases in combination with an ERR-β agonist shifts isoform expression in favor of ERR-β2 and potentiates inhibition of growth and migration in GBM cells and intracranial tumors.-Tiek, D. M., Khatib, S. A., Trepicchio, C. J., Heckler, M. M., Divekar, S. D., Sarkaria, J. N., Glasgow, E., Riggins, R. B. Estrogen-related receptor β activation and isoform shifting by cdc2-like kinase inhibition restricts migration and intracranial tumor growth in glioblastoma.

Entities:  

Keywords:  CLK; ERR-β; GBM; alternative splicing; cortactin

Mesh:

Substances:

Year:  2019        PMID: 31570001      PMCID: PMC6894094          DOI: 10.1096/fj.201901075R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.834


  55 in total

1.  Scansite 2.0: Proteome-wide prediction of cell signaling interactions using short sequence motifs.

Authors:  John C Obenauer; Lewis C Cantley; Michael B Yaffe
Journal:  Nucleic Acids Res       Date:  2003-07-01       Impact factor: 16.971

2.  Actin stress fibers--assembly, dynamics and biological roles.

Authors:  Sari Tojkander; Gergana Gateva; Pekka Lappalainen
Journal:  J Cell Sci       Date:  2012-04-29       Impact factor: 5.285

3.  The SH3 domain of amphiphysin binds the proline-rich domain of dynamin at a single site that defines a new SH3 binding consensus sequence.

Authors:  D Grabs; V I Slepnev; Z Songyang; C David; M Lynch; L C Cantley; P De Camilli
Journal:  J Biol Chem       Date:  1997-05-16       Impact factor: 5.157

4.  Establishment, maintenance and in vitro and in vivo applications of primary human glioblastoma multiforme (GBM) xenograft models for translational biology studies and drug discovery.

Authors:  Brett L Carlson; Jenny L Pokorny; Mark A Schroeder; Jann N Sarkaria
Journal:  Curr Protoc Pharmacol       Date:  2011-03

5.  Changes in tumor cell heterogeneity after chemotherapy treatment in a xenograft model of glioblastoma.

Authors:  Alessandra M Welker; Brian D Jaros; Min An; Christine E Beattie
Journal:  Neuroscience       Date:  2017-05-17       Impact factor: 3.590

6.  A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.

Authors:  Séverine Coutadeur; Hélène Benyamine; Laurence Delalonde; Catherine de Oliveira; Bertrand Leblond; Alicia Foucourt; Thierry Besson; Anne-Sophie Casagrande; Thierry Taverne; Angélique Girard; Matthew P Pando; Laurent Désiré
Journal:  J Neurochem       Date:  2015-01-26       Impact factor: 5.372

7.  Orphan nuclear receptor estrogen-related receptor-beta suppresses in vitro and in vivo growth of prostate cancer cells via p21(WAF1/CIP1) induction and as a potential therapeutic target in prostate cancer.

Authors:  S Yu; Y C Wong; X H Wang; M T Ling; C F Ng; S Chen; F L Chan
Journal:  Oncogene       Date:  2007-12-10       Impact factor: 9.867

Review 8.  Zebrafish: a new companion for translational research in oncology.

Authors:  Jorge Barriuso; Raghavendar Nagaraju; Adam Hurlstone
Journal:  Clin Cancer Res       Date:  2015-01-08       Impact factor: 12.531

9.  Standardized orthotopic xenografts in zebrafish reveal glioma cell-line-specific characteristics and tumor cell heterogeneity.

Authors:  Alessandra M Welker; Brian D Jaros; Vinay K Puduvalli; Jaime Imitola; Balveen Kaur; Christine E Beattie
Journal:  Dis Model Mech       Date:  2015-12-10       Impact factor: 5.758

10.  Antimitotic activity of DY131 and the estrogen-related receptor beta 2 (ERRβ2) splice variant in breast cancer.

Authors:  Mary M Heckler; Tizita Zewde Zeleke; Shailaja D Divekar; Aileen I Fernandez; Deanna M Tiek; Jordan Woodrick; Alexander Farzanegan; Rabindra Roy; Aykut Üren; Susette C Mueller; Rebecca B Riggins
Journal:  Oncotarget       Date:  2016-07-26
View more
  6 in total

Review 1.  Zebrafish Xenografts for Drug Discovery and Personalized Medicine.

Authors:  Jerry Xiao; Eric Glasgow; Seema Agarwal
Journal:  Trends Cancer       Date:  2020-04-17

Review 2.  Estrogen-related receptors: novel potential regulators of osteoarthritis pathogenesis.

Authors:  Jinshuo Tang; Tong Liu; Xinggui Wen; Zhongsheng Zhou; Jingtong Yan; Jianpeng Gao; Jianlin Zuo
Journal:  Mol Med       Date:  2021-01-15       Impact factor: 6.354

3.  Norcantharidin overcomes vemurafenib resistance in melanoma by inhibiting pentose phosphate pathway and lipogenesis via downregulating the mTOR pathway.

Authors:  Lei Wang; Wuxiyar Otkur; Aman Wang; Wen Wang; Yitong Lyu; Lei Fang; Xiu Shan; Mingzhou Song; Yan Feng; Yi Zhao; Hai-Long Piao; Huan Qi; Ji-Wei Liu
Journal:  Front Pharmacol       Date:  2022-08-12       Impact factor: 5.988

4.  Mass spectrometry imaging discriminates glioblastoma tumor cell subpopulations and different microvascular formations based on their lipid profiles.

Authors:  Kelly C O'Neill; Evangelos Liapis; Brent T Harris; David S Perlin; Claire L Carter
Journal:  Sci Rep       Date:  2022-10-12       Impact factor: 4.996

Review 5.  RNA modifications in brain tumorigenesis.

Authors:  Albert Z Huang; Alberto Delaidelli; Poul H Sorensen
Journal:  Acta Neuropathol Commun       Date:  2020-05-06       Impact factor: 7.801

Review 6.  Splicing Dysregulation as Oncogenic Driver and Passenger Factor in Brain Tumors.

Authors:  Pamela Bielli; Vittoria Pagliarini; Marco Pieraccioli; Cinzia Caggiano; Claudio Sette
Journal:  Cells       Date:  2019-12-18       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.